Generic Medicine Info
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Hypersensitivity to aciclovir and similar antivirals e.g. valaciclovir.
Special Precautions
Immunocompromised patients. Patient receiving high doses. Ensure adequate hydration. Avoid extravasation. Renal impairment. Children. Pregnancy and lactation. Monitoring Parameters Monitor urinalysis, BUN, serum creatinine, urine output, liver enzymes, CBC. Assess for neurotoxicity and nephrotoxicity in paediatric patients receiving high doses. Monitor neutrophil count at least twice weekly in neonates.
Adverse Reactions
Significant: Contact sensitisation (topical). Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain. General disorders and administration site conditions: Fatigue, fever. Investigations: Increased liver enzymes (reversible), BUN and creatinine. Nervous system disorders: Headache, dizziness. Skin and subcutaneous tissue disorders: Pruritus, rash, photosensitivity, urticaria, accelerated diffuse hair loss. Vascular disorders: Phlebitis (IV).
Potentially Fatal: Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome (immunocompromised patients). Renal failure.
Drug Interactions
Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. May increase the serum concentration of theophylline. May increase risk of renal impairment with nephrotoxic drugs.
CIMS Class
Antivirals / Eye Anti-Infectives & Antiseptics / Topical Antivirals
ATC Classification
S01AD03 - aciclovir ; Belongs to the class of antiinfectives, antivirals. Used in the treatment of eye infections.
D06BB03 - aciclovir ; Belongs to the class of topical antivirals used in the treatment of dermatological diseases.
J05AB01 - aciclovir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on aciclovir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in